Kiladjian, J., Zachee, P., Hino, M., et al. (2020) Long-Term Efficacy and Safety of Ruxolitinib versus Best Available Therapy in Polycythaemia Vera (RESPONSE): 5-Year Follow up of a Phase 3 Study. The Lancet Haematology, 7, E226-E237.
https://doi.org/10.1016/S2352-3026(19)30207-8

has been cited by the following article:

• TITLE: Does Ruxolitinib, in Comparison to Best Available Therapy (BAT), Improve Pruritis Symptoms in Patients with Polycythemia Vera?

  AUTHORS: Zachary Samuel Thorogood

  KEYWORDS: Polycythemia Vera, Ruxolitinib, Pruritis

  JOURNAL NAME: Journal of Biosciences and Medicines, Vol.12 No.3, March 8, 2024

  ABSTRACT: Polycythemia vera manifests as a myeloproliferative neoplasm associated with diverse symptoms, including aquagenic pruritis. This systematic review addresses the pressing need to enhance the understanding of the disease’s symptomatology and optimize treatment strategies for improved patient outcomes. The rarity and low prevalence of polycythemia vera underscore the importance of this investigation, as existing standard of care involves a multifaceted approach and significant healthcare costs. Despite advancement in therapeutic options, persistent symptoms and resistance to first-line treatments pose challenges. Ruxolitinib has emerged as a promising intervention, demonstrating clinically significant improvement for patients. This systematic review appraises three randomized controlled trials, shedding light on the efficacy of ruxolitinib and its potential to ameliorate pruritis symptoms in symptomatic patients.